Mylan rolls out Hepatitis C drug

Highlights

Mylan Pharmaceuticals Private Limited, a subsidiary of Mylan NV, on Thursday launched generic Harvoni (Ledipasvir 90 mg/Sofosbuvir 400 mg) tablets under the brand name MyHep LVIR™ in India.

Hyderabad: Mylan Pharmaceuticals Private Limited, a subsidiary of Mylan NV, on Thursday launched generic Harvoni (Ledipasvir 90 mg/Sofosbuvir 400 mg) tablets under the brand name MyHep LVIRTM in India.

The Ledipasvir/Sofosbuvir combination is indicated for the treatment of Hepatitis C infection and offers a simplified treatment regimen that eliminates the need for interferon and ribavirin. The product also is a single-tablet regimen and requires a therapy course of just 12 weeks.

Harvoni has exhibited high cure rates and a tolerable side effect profile across a range of patient populations, the company said in a release. “Mylan recognises the urgent need to expand access to high quality, affordable Hepatitis C treatment options in India, where roughly 12 million people are infected with the virus.

MyHep LVIRTM is an important addition to our growing Hepato Care segment in India that gives us the opportunity to offer patients the potential to be cured through a transformative and simplified single tablet, once-daily treatment regimen,” said Rajiv Malik, President, Mylan.

Moreover, consistent with our commitment to create better health for a better world, we are introducing various educational initiatives in India to raise awareness of the disease and its treatment options, he added.

The latest roll-out comes close on the heels of the launch of generic Sofosbuvir in India under the brand name MyHepTM in April 2015. In September 2014, Mylan entered into a licensing and technology transfer agreement with Gilead that granted Mylan the non-exclusive rights to manufacture and distribute generic Sofosbuvir and Ledipasvir/Sofosbuvir tablets in 101 developing countries, including India.

Show Full Article
Download The Hans India Android App or iOS App for the Latest update on your phone.
More Stories


Top